MedTrace Logo

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

NCT01350141 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-11-08

Study results available
· View outcomes & findings →

Summary

PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.

Conditions

Interventions

OTHER

Placebo

An infusion lasting approximately 60 minutes

DRUG

PF-04950615 (RN316)

An infusion lasting approximately 60 minutes

DRUG

PF-04950615 (RN316)

An infusion lasting approximately 60 minutes

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-04-30
Completion
2012-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01350141 on ClinicalTrials.gov